Sangamo Therapeutics (SGMO) Reports Positive Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. PLTR
2. TMUS
3. LBRX
4. BMY
5. MRK
6. TRAX
7. SPY
8. MSFT
9. AON
10. DMART:IN

Go back to Sangamo Therapeutics (SGMO) Reports Positive Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data

Sangamo Therapeutics Announces Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and Sustained Effects in Sickle Cell Disease

December 12, 2021 9:00 AM EST

- No adverse events related to investigational SAR445136 were reported
- All four treated patients experienced increases in total hemoglobin, fetal hemoglobin and percent F cells; none required blood transfusions post engraftment

BRISBANE, Calif.--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary proof-of-concept clinical data from the Phase 1/2 PRECIZN-1 study of SAR445136, a zinc finger nuclease gene-edited cell therapy candidate in development with Sanofi for the treatment of sickle cell disease (SCD). These data are being presented today at the 63rd... More